A world first implantation of a high-tech, battery-powered device to restore erectile function, has taken place at the Royal Melbourne Hospital (RMH) leading a global trial. Comphya’s CaverSTIM is the first implantable ‘neurostimulator’ for erectile dysfunction treatment, designed for patients that are non-responders to oral drugs, including spinal cord-injured patients and post-prostatectomy patients.
Consulting Urologist at the RMH and Clinical Director at the Australian Prostate Centre (APC), Dr Phil Dundee conducted the successful operation on August 3rd. The first-in-human clinical safety trial for the ground-breaking treatment is a collaboration between the APC, the RMH and Swiss MedTech company Comphya SA.
CaverSTIM is a ‘neurostimulation’ system composed of an implantable pulse generator (IPG), containing rechargeable battery and electronics for the generation of an electrostimulation signal; implanted in the pelvic cavity to activate and restore the nerves responsible for penile erection. The IPG once surgically inserted in the lower abdomen, is remotely operated by external controllers. The clinician controller allows the medical expert to adjust and tailor the system parameters to best fit each patient, and the patient controller allows the patient to activate the device and evoke a penile erection.
“It’s truly exciting to be part of such innovation particularly when we know this treatment has the potential to be life-changing for millions of patients world-wide,” said Dr. Phil Dundee. “As we initiate this clinical trial, we celebrate the culmination of our team’s steadfast dedication and hard work in developing our unique CaverSTIM system,” said Rodrigo Fraga-Silva, CEO and Co-founder of Comphya SA.
(Press release / SK)
Please login or sign up to comment.
Commenting guidelines